Mirati Therapeutics, a clinical stage targeted oncology company, announced changes to its executive management team, including the promotion of Vickie Reed to senior vice president, finance and chief accounting officer.

Reed has been with Mirati for six years and has worked in roles of increasing responsibility during that time. She has over 20 years of biotech experience and has expertise in Sarbanes-Oxley Act compliance, resolution of complex accounting issues, and process improvement to maximize corporate finance performance.

Other appointments by Mirati include Daniel Faga as executive vice president, chief operating officer, and Benjamin Hickey as executive vice president, chief commercial officer.